Ex Parte KRIEGER - Page 5

                Appeal  2007-4148                                                                              
                Application 09/148,012                                                                         

                and preparation of receptor protein fragments (id. at 24-25).  Finally, the                    
                Specification describes a working example in which antibodies to “mSR-BI”                      
                (murine SR-BI; id. at 40: 26) were raised and combined in vitro with                           
                SR-BI-expressing adrenocortical cells to determine the effect of the antibody                  
                on HDL uptake and steroid production (id. at 55-66).                                           
                      Thus, the Specification does not describe any structural features that                   
                are shared by compounds having the function of “inhibiting uptake, binding                     
                or transport of cholesteryl ester by SR-BI.”  The Specification describes two                  
                polyclonal antibody preparations that contain antibodies to murine SR-BI.                      
                The Specification discloses the amino acid sequence of murine SR-BI (SEQ                       
                ID NO: 4), and therefore the disclosed antibodies are adequately described.                    
                See Noelle v. Lederman, 355 F.3d 1343, 1349 (Fed. Cir. 2004).                                  
                      However, the Specification describes no other specific compounds                         
                having the function of “inhibiting uptake, binding or transport of cholesteryl                 
                ester by SR-BI.”  The present case is therefore analogous to Rochester.  In                    
                that case, the patent claimed a method of selectively inhibiting the enzyme                    
                PGHS-2 (also known as COX-2) by “administering a non-steroidal                                 
                compound that selectively inhibits activity of the PGHS-2 gene product to a                    
                human.”  358 F.3d at 918.  The patent “described in detail how to make cells                   
                that express either COX-1 or COX-2, but not both . . . , as well as ‘assays for                
                screening compounds, including peptides, polynucleotides, and small                            
                organic molecules to identify those that inhibit the expression or activity of                 
                the PGHS-2 gene product.[’]”  Id. at 927.                                                      
                      The court held that the disclosure of screening assays and general                       
                classes of compounds was not adequate to describe compounds having the                         


                                                      5                                                        

Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  14  Next

Last modified: September 9, 2013